AUS
NZ
UK
CA
USA
IND
Highlights
- Disc Medicine raises $225.5 million in upsized public offering of common stock and warrants.
- Funds will support research, clinical development, and commercialization of bitopertin for EPP and XLP.
- Offering led by Jefferies, Leerink Partners, and other top investment banks.
Disc Medicine (NASDAQ:IRON), a biopharmaceutical company focused on developing therapies for rare hematologic diseases, has announced the pricing of its upsized public offering, raising approximately $225.5 million in gross proceeds. The offering consists of 3,918,182 shares of common stock priced at $55.00 per share, along with pre-funded warrants to purchase 181,818 shares at $54.9999 per warrant. The company has granted underwriters a 30-day option to purchase up to an additional $33.825 million in shares, bringing the total potential proceeds to over $250 million.
The offering, which is expected to close on January 24, 2025, will provide Disc Medicine with significant capital to advance its clinical pipeline, particularly its lead candidate, bitopertin. The proceeds will be allocated to support research and clinical development for bitopertin in treating Erythropoietic Protoporphyria (EPP) and X-linked Protoporphyria (XLP), as well as to fund the potential commercialization of the drug. This strategic focus on rare hematologic diseases positions Disc Medicine to make meaningful advancements in treating conditions with limited therapeutic options.
The offering is being managed by a strong syndicate of investment banks, including Jefferies, Leerink Partners, Stifel, and Cantor as joint book-running managers. BMO Capital Markets, LifeSci Capital, Wedbush PacGrow, and H.C. Wainwright & Co. are serving as co-managers. This diverse group of experienced underwriters underscores the market confidence in Disc Medicine’s clinical prospects and financial strategy.
While the capital raised is significant and will support critical R&D initiatives, the offering also introduces potential challenges for existing shareholders. The issuance of new shares and warrants will result in shareholder dilution. Additionally, there is a possibility of further dilution if the underwriters exercise their option to purchase additional shares. Although this offering provides substantial funds for the company’s development efforts, it also highlights the trade-off between securing necessary funding and the impact on existing equity holders.
Disc Medicine’s focus on advancing bitopertin for rare diseases like EPP and XLP has the potential to provide substantial clinical benefits, as these conditions currently lack effective treatments. As the company moves forward with its clinical programs and commercialization plans, investors will be closely watching the progress of its trials and the potential regulatory approval of bitopertin.
With the financial backing from this offering and a solid pipeline, Disc Medicine is positioned to continue its work in addressing unmet needs in rare hematologic diseases, while managing the challenges of shareholder dilution and market expectations.
